{"id":55473,"date":"2024-10-03T09:58:17","date_gmt":"2024-10-03T13:58:17","guid":{"rendered":"https:\/\/www.businessupturn.com\/usa\/?p=55473"},"modified":"2024-10-03T09:58:17","modified_gmt":"2024-10-03T13:58:17","slug":"astrazeneca-stock-rises-on-collaboration-with-arcus-biosciences-for-renal-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.businessupturn.com\/usa\/astrazeneca-stock-rises-on-collaboration-with-arcus-biosciences-for-renal-cancer-treatment\/55473\/","title":{"rendered":"AstraZeneca stock rises on collaboration with Arcus Biosciences for renal cancer treatment"},"content":{"rendered":"

Shares of AstraZeneca PLC surged 4.3% amidst high trading volume following the announcement of a new trial collaboration with Arcus Biosciences. The partnership aims to target clear cell renal cell carcinoma (ccRCC), a type of kidney cancer.<\/p>\n

Details of the Collaboration<\/h3>\n

Arcus Biosciences and AstraZeneca will work together on a clinical trial to evaluate a combination of two investigational drugs: casdatifan (AB521) and volrustomig. Casdatifan, developed by Arcus, is a HIF-2a inhibitor, while volrustomig, from AstraZeneca, is a PD-1\/CTLA-4 bispecific antibody.<\/p>\n

The collaboration involves AstraZeneca sponsoring and managing the trial. The study will focus on assessing both the safety and early efficacy of the combination therapy in patients with advanced ccRCC.<\/p>\n

Statements from Arcus Biosciences<\/h3>\n

Terry Rosen, CEO of Arcus Biosciences, shared optimism about the potential of casdatifan. \u201cWe believe casdatifan has best-in-class potential, based on the observed PK and PD profiles and the emerging clinical data from our ARC-20 study in patients with ccRCC,\u201d he said. Rosen also noted that the collaboration would allow both companies to explore the potential benefits of combining casdatifan and volrustomig for ccRCC patients.<\/p>\n

This partnership is a strategic step towards developing new treatments for renal cell carcinoma, aiming to improve outcomes for affected patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of AstraZeneca PLC surged 4.3% amidst high trading volume following the announcement of a new trial collaboration with Arcus\u2026<\/p>\n","protected":false},"author":432,"featured_media":52611,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[19173],"class_list":["post-55473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets","tag-astrazeneca"],"reading_time":"2 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/55473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/432"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=55473"}],"version-history":[{"count":0,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/55473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/52611"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=55473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=55473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=55473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}